BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:A2B395 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of A2B395\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06682793-2309@assetmemo.bio
DTSTAMP:20261121T005338Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:A2B395: Phase 1/2 readout est. (NCT06682793)
DESCRIPTION:A2B395\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Stud
 y to Evaluate the Safety and Efficacy of A2B395\, an Allogeneic Logic-gate
 d CAR T\, in Participants With Solid Tumors That Express EGFR and Have Los
 t HLA-A*02 Expression\nEstimated primary completion: 31 March 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/a2b395#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06682793
URL:https://assetmemo.bio/drug/a2b395#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
